Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial
AR Parikh, A Szabolcs, JN Allen, JW Clark, JY Wo… - Nature cancer, 2021 - nature.com
Overcoming intrinsic resistance to immune checkpoint blockade for microsatellite stable
(MSS) colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) remains …
(MSS) colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) remains …
[HTML][HTML] Biomarkers of response and resistance to immunotherapy in microsatellite stable colorectal cancer: toward a new personalized medicine
N Huyghe, E Benidovskaya, P Stevens… - Cancers, 2022 - mdpi.com
Simple Summary Immune Checkpoint Inhibitors (ICIs) have demonstrated clinical efficacy in
Microsatellite Instability High Colorectal Cancer (MSI-H CRC). However, in Microsatellite …
Microsatellite Instability High Colorectal Cancer (MSI-H CRC). However, in Microsatellite …
Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022
Immune checkpoint inhibitors (ICIs) are shown to be effective among patients with metastatic
colorectal cancer (mCRC) harboring high microsatellite instability (MSI-H) and/or mismatch …
colorectal cancer (mCRC) harboring high microsatellite instability (MSI-H) and/or mismatch …
Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.
LA Diaz, A Marabelle, JP Delord, R Shapira-Frommer… - 2017 - ascopubs.org
3071 Background: Mismatch repair deficient cancers harbor high levels of microsatellite
instability and somatic mutations. Treatment with anti-PD-1 antibodies has resulted in …
instability and somatic mutations. Treatment with anti-PD-1 antibodies has resulted in …
[HTML][HTML] Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
J Ros, F Balconi, I Baraibar, N Saoudi Gonzalez… - Frontiers in …, 2023 - frontiersin.org
Immune checkpoint inhibitors have reshaped the prognostic of several tumor types,
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …
[HTML][HTML] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4 …
Background In the phase II multicohort CheckMate 142 study, nivolumab plus low-dose (1
mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety …
mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety …
[HTML][HTML] Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint …
DA Fabrizio, TJ George Jr, RF Dunne… - Journal of …, 2018 - ncbi.nlm.nih.gov
Background The clinical application of PD1/PD-L1 targeting checkpoint inhibitors in
colorectal cancer (CRC) has largely focused on a subset of microsatellite instable (MSI-high) …
colorectal cancer (CRC) has largely focused on a subset of microsatellite instable (MSI-high) …
Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite …
Importance Microsatellite stable (MSS) metastatic colorectal cancer has been historically
characterized as resistant to immunotherapy. Recent studies have demonstrated limited …
characterized as resistant to immunotherapy. Recent studies have demonstrated limited …
Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues
With the development of immune checkpoint inhibitors, immunotherapy researchers have
facilitated substantial progress for patients with mismatch repair deficient/microsatellite …
facilitated substantial progress for patients with mismatch repair deficient/microsatellite …
[HTML][HTML] Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
Background Microsatellite instability in colon cancer implies favorable therapeutic outcomes
after checkpoint blockade immunotherapy. However, the molecular nature of microsatellite …
after checkpoint blockade immunotherapy. However, the molecular nature of microsatellite …